Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Platelet lysate (PL) is an attractive platelet-based therapeutic tool and has shown promise as xeno-free replacement for fetal bovine serum (FBS) in human and equine mesenchymal stromal cell (MSC) culture. Here, we established a scalable buffy-coat-based protocol for canine PL (cPL) production (n = 12). The cPL was tested in canine adipose MSC (n = 5) culture compared to FBS. For further comparison, equine adipose MSC (n = 5) were cultured with analogous equine PL (ePL) or FBS. During canine blood processing, platelet and transforming growth factor-β1 concentrations increased ( < 0.05 and < 0.001), while white blood cell concentrations decreased ( < 0.05). However, while equine MSC showed good results when cultured with 10% ePL, canine MSC cultured with 2.5% or 10% cPL changed their morphology and showed decreased metabolic activity ( < 0.05). Apoptosis and necrosis in canine MSC were increased with 2.5% cPL ( < 0.05). Surprisingly, passage 5 canine MSC showed less genetic aberrations after culture with 10% cPL than with FBS. Our data reveal that using analogous canine and equine biologicals does not entail the same results. The buffy-coat-based cPL was not adequate for canine MSC culture, but may still be useful for therapeutic applications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773277PMC
http://dx.doi.org/10.3390/ani12020189DOI Listing

Publication Analysis

Top Keywords

canine msc
16
msc culture
12
canine
9
platelet lysate
8
mesenchymal stromal
8
stromal cell
8
canine equine
8
msc
8
adipose msc
8
msc cultured
8

Similar Publications

Canine somatic cell nuclear transfer (SCNT) is a powerful technology that can be used to clone beloved companion dogs, produce valuable working dogs, rescue endangered canine breeds, and create genetically engineered dogs. Nevertheless, the application of this technology is hindered by the low developmental efficiency of canine SCNT embryos. It has been shown that in pig and horse cloning using mesenchymal stem cells (MSCs), compared with fibroblasts, as donor cells can enhance the developmental potential of SCNT embryos.

View Article and Find Full Text PDF

This study evaluates the clinical efficacy and safety of intravenous allogeneic mesenchymal stem cell (MSC) therapy as an adjunct to standard immunosuppressive treatment in dogs diagnosed with primary immune-mediated hemolytic anemia (IMHA), particularly in cases with inadequate response to conventional immunosuppressive protocols. A total of 157 client-owned dogs with IMHA received MSC therapy at Safari Veterinary Care Center or collaborating clinics. A core cohort of 43 dogs met strict inclusion criteria: confirmed primary IMHA, no significant comorbidities, and receipt of at least two MSC treatments.

View Article and Find Full Text PDF

Refractory immune-mediated thrombocytopenia (ITP) in dogs is a condition with a poor prognosis due to the poor response to immunosuppressive therapy and the adverse effects of long-term drug administration. This case report describes the successful management of refractory ITP using stem cell therapy in a dog that experienced severe side effects from immunosuppressive treatment. The patient experienced recurrent relapses when prednisolone (PDS) tapering was attempted during conventional immunosuppressive therapy, necessitating prolonged use of PDS; this led to complications, such as diabetic ketoacidosis and chronic gastrointestinal bleeding.

View Article and Find Full Text PDF

Mesenchymal stem cell (MSC) therapy is a promising approach for treating orthopaedic conditions in veterinary clinical patients. MSCs exhibit remarkable regenerative properties, including multilineage differentiation, immunomodulation, and tissue repair, making them an attractive alternative to conventional therapies. This comprehensive review explores the clinical potential of MSCs in managing a range of canine orthopaedic disorders, including fractures, degenerative joint diseases, and tendon injuries.

View Article and Find Full Text PDF

Background: Early treatment of Class III malocclusion in growing patients remains a significant orthodontic challenge due to unfavorable growth patterns. This study evaluates the positional changes of the maxillary permanent canines (Mx3) and the first maxillary permanent molars (Mx6) after early treatment of Class III malocclusion with maxillary expansion and protraction (MEP).

Material And Methods: A retrospective cohort study was conducted, including a longitudinal and panoramic radiographic (panorex) analysis.

View Article and Find Full Text PDF